Erica Kretchman, DO
Endocrinology, Diabetes & Metabolism · Richmond, INNPI 1003013673
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $495,268 of the $608,564 with a category attached, or 81.4%. 56 manufacturers reported payments, led by Novo Nordisk at 37.4% of the total. Among endocrinology, diabetes & metabolism clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,915 payments — averaging $317.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$227K
- Lilly USA, LLC$188K
- Medtronic$51K
- AstraZeneca$44K
- Abbott$32K
- Boehringer Ingelheim$26K
- plus $40K from 50 others
Across 15 payments — averaging $1834.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$28K
What the payments were for
- Consulting fees$3,6131%
- Speaking & faculty fees$495,26881%
- Travel & lodging$80,04413%
- Food & beverage$29,4115%
- Education$1700%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$113,551
- RYBELSUS$109,890
- Ozempic$94,554
- JARDIANCE$46,960
- FARXIGA$42,529
- Minimed 630G$27,875
- V-GO$24,506
- FreeStyle Libre Pro$19,572
- InPen$13,000
- LYUMJEV$8,363
- FREESTYLE LIBRE 3$6,903
- FreeStyle Libre$4,966
- DEXCOM G6 CGM SYSTEM$3,417
- Minimed 670G System$2,683
- Guardian Connect$1,500
- iPro2$1,250
- MINIMED 770G$1,000
- MiniLink Real-Time Transmitter$750
- V-GO DISPOSABLE INSULIN DELIVERY$600
- Minimed 770G System$250
How this compares
$608,564 in reported general payments places this provider in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 564 | $995,244 |
| MounjaroTirzepatide | 392 | $546,034 |
| KorlymMifepristone | 21 | $528,528 |
| JardianceEmpagliflozin | 359 | $389,763 |
| FarxigaDapagliflozin Propanediol | 273 | $299,483 |
| Tresiba Flextouch U-200Insulin Degludec | 185 | $186,759 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 137 | $158,110 |
| Tresiba Flextouch U-100Insulin Degludec | 209 | $132,535 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 44 | $94,478 |
| TrulicityDulaglutide | 58 | $86,504 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $82,310 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 67 | $81,975 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $68,871 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $58,977 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $57,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Wegovy, Rybelsus, Novolog | $227,394 | $1,124,792669 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $187,703 | $664,920544 claims |
| Corcept TherapeuticsKorlym | $1,468 | $528,52821 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $25,573 | $472,693426 claims |
| AstraZenecaFarxiga | $44,214 | $299,483273 claims |
| MerckJanuvia | $242 | $28,91031 claims |
| AbbVieSynthroid | $146 | $19,980203 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $902 | $16,10114 claims |
| BayerKerendia | $578 | $10,80311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Richmond
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
- Pooja KinkhabwalaMerrillville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.